Can a Two-Drug combo wipe out hidden leukemia cells?

NCT ID NCT07734038

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining venetoclax and zanubrutinib can drive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) into deep remission. The study enrolls adults who either have not been treated before or whose cancer returned at least two years after finishing initial therapy. Participants receive both drugs for up to 24 cycles, and researchers measure whether cancer cells become undetectable in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of venetoclax and zanubrutinib
What this could lead to
If successful, this combination could offer a more effective, time-limited treatment for CLL/SLL, potentially achieving deep remission without continuous therapy.
What could go wrong
This is a phase 2 trial, so results are still uncertain. The combination may cause side effects or fail to produce lasting remission in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.